TipRanks
Advertisement
Advertisement

CGEM Stock Latest News

Cullinan Therapeutics doses first patient in CLN-049 trial
The FlyCullinan Therapeutics doses first patient in CLN-049 trial
9d ago
CGEM
Cullinan Management Advances NDA for Zipalertinib Combination
PremiumCompany Announcements
Cullinan Management Advances NDA for Zipalertinib Combination
15d ago
8K
CGEM
Cullinan Therapeutics initiates NDA for Zipalertinib
PremiumThe Fly
Cullinan Therapeutics initiates NDA for Zipalertinib
15d ago
CGEM
Cullinan Therapeutics price target raised to $35 from $30 at H.C. Wainwright
PremiumThe Fly
Cullinan Therapeutics price target raised to $35 from $30 at H.C. Wainwright
22d ago
CGEM
Matt Phipps Reiterates Buy on Cullinan Oncology, Citing Pullback-Driven Upside and Upcoming Q4 Clinical Data Catalysts
PremiumRatings
Matt Phipps Reiterates Buy on Cullinan Oncology, Citing Pullback-Driven Upside and Upcoming Q4 Clinical Data Catalysts
22d ago
CGEM
Cullinan Therapeutics share weakness provides buying opportunity, says TD Cowen
PremiumThe FlyCullinan Therapeutics share weakness provides buying opportunity, says TD Cowen
22d ago
CGEM
Cullinan falls after pushing rheumatoid arthritis data to December
Premium
The Fly
Cullinan falls after pushing rheumatoid arthritis data to December
23d ago
CGEM
Cullinan Management Highlights Q4 T Cell Engager Milestones
Premium
Company Announcements
Cullinan Management Highlights Q4 T Cell Engager Milestones
23d ago
8K
CGEM
Cullinan Therapeutics outlines Q4 2026 milestones across pipeline
PremiumThe Fly
Cullinan Therapeutics outlines Q4 2026 milestones across pipeline
23d ago
CGEM
Cullinan Maintained at Buy on Zipalertinib Strength, Unchanged $33 Price Target
PremiumRatings
Cullinan Maintained at Buy on Zipalertinib Strength, Unchanged $33 Price Target
1M ago
CGEM
Cullinan Therapeutics price target raised to $40 from $39 at BTIG
PremiumThe Fly
Cullinan Therapeutics price target raised to $40 from $39 at BTIG
1M ago
CGEM
Cullinan Highlights Positive Phase 3 Lung Cancer Results
PremiumCompany Announcements
Cullinan Highlights Positive Phase 3 Lung Cancer Results
1M ago
8K
CGEM
Matt Phipps Reiterates Buy on Cullinan After Strong Phase III REZILIENT3 Data for Zipalertinib in First-Line EGFR Exon 20–Mutant NSCLC
PremiumRatingsMatt Phipps Reiterates Buy on Cullinan After Strong Phase III REZILIENT3 Data for Zipalertinib in First-Line EGFR Exon 20–Mutant NSCLC
1M ago
CGEM
Boris Peaker Reiterates Buy on Cullinan, Maintains $36 Price Target on Strong Zipalertinib Data and CLN-978-Driven Valuation
Premium
Ratings
Boris Peaker Reiterates Buy on Cullinan, Maintains $36 Price Target on Strong Zipalertinib Data and CLN-978-Driven Valuation
1M ago
CGEM
Cullinan, Taiho announce Phase 3 REZILIENT3 trial met primary endpoint
Premium
The Fly
Cullinan, Taiho announce Phase 3 REZILIENT3 trial met primary endpoint
1M ago
CGEM
Cullinan, Taiho say results of Phase 3 trial selected for presentation
PremiumThe Fly
Cullinan, Taiho say results of Phase 3 trial selected for presentation
2M ago
CGEM
Analyst Reiterates Buy on Cullinan as Zipalertinib Progress Supports NDA Path; $30 Price Target Maintained
PremiumRatings
Analyst Reiterates Buy on Cullinan as Zipalertinib Progress Supports NDA Path; $30 Price Target Maintained
2M ago
CGEM
Taiho, Cullinan Therapeutics study demonstrates statistically significant PFS
PremiumThe Fly
Taiho, Cullinan Therapeutics study demonstrates statistically significant PFS
2M ago
CGEM
Cullinan Therapeutics price target raised to $47 from $46 at Clear Street
PremiumThe Fly
Cullinan Therapeutics price target raised to $47 from $46 at Clear Street
2M ago
CGEM
Strong Phase III Zipalertinib Data and Taiho Partnership Drive Matt Phipps’ Buy Rating on Cullinan for Favorable Risk‑Reward
PremiumRatingsStrong Phase III Zipalertinib Data and Taiho Partnership Drive Matt Phipps’ Buy Rating on Cullinan for Favorable Risk‑Reward
2M ago
CGEM
Cullinan Reports Positive Phase 3 Zipalertinib Lung Cancer Data
Premium
Company Announcements
Cullinan Reports Positive Phase 3 Zipalertinib Lung Cancer Data
2M ago
8K
CGEM
Cullinan Oncology: Buy Rating Reaffirmed with Unchanged $30 Price Target on Robust Pipeline and Strong Cash Position
Premium
Ratings
Cullinan Oncology: Buy Rating Reaffirmed with Unchanged $30 Price Target on Robust Pipeline and Strong Cash Position
2M ago
CGEM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >